Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial ...

Johnson & Johnson bought the full rights to a rare disease gene therapy a few years ago, but now the Big Pharma may be ...

Researchers have found in a new study involving 89 amblyopia patients, including adults, that visual acuity gradually ...

Nearsightedness is the ability to see clearly up close but makes you unable to see far-away objects clearly. However, ...

GreenShield Hospital in collaboration with HCP and Eye Care Secretariat has successfully completed its free cataract surgery ...

Adyanthaya, MD: One of the problems in early diagnosis of geographic atrophy is that when visual acuity is tested with the Snellen chart ... and warrant a dilated eye exam and macular scans.

Researchers investigated the concurrent validity of various visual function measures in differentiating early and ...

Hard on the heels of some impressive clinical trial results, Luminopia has won FDA approval for its digital therapeutic (DTx) for amblyopia or lazy eye in ... to improve visual acuity in children ...

Award-winning research shows RevitalVision improves vision in keratoconus and post-cataract patients, highlighting rising ...

Beacon Therapeutics may have found a guiding light in a disease area where other companies have stumbled with its ...

The trial aims to assess the tolerability and safety of the sealant within the first 16 weeks after pars plana vitrectomy.

positive in vivo confocal microscopy findings (decreased nerve density and evidence of microneuromas), and a best corrected distance visual acuity of at least +1.0 LogMAR in the study eye.